Twist Bioscience Corp Dossier
Qualitative Analysis
Business overview
Twist Bioscience Corporation is a leading synthetic biology and genomics company that has developed a disruptive DNA synthesis platform. The core of its platform is a proprietary semiconductor-based technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip rather than traditional plastic plates. This miniaturization allows Twist to synthesize high-quality DNA faster, more affordably, and at a scale previously unattainable. The company's products serve life sciences researchers across a variety of applications, including therapeutics (antibody discovery), diagnostics (Next-Generation Sequencing target enrichment), industrial chemicals, agriculture, and digital data storage in DNA.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Scaling the core synthetic biology franchise by leveraging the proprietary silicon-based DNA synthesis platform to improve throughput, quality, and turnaround times. This includes driving penetration of the premium, speed-focused 'Express Genes' portfolio into academic, biopharma, and industrial biology markets.
Expected impact: Expands customer accounts, lowers customer acquisition costs via digital-first e-commerce, and drives higher-margin revenue mix shifts.
Building the Next-Generation Sequencing (NGS) business into a larger recurring consumables engine by expanding target enrichment panels, library preparation tools, and native workflow kits compatible with major sequencing platforms.
Expected impact: Diversifies revenue streams and embeds Twist's tools deeply into clinical oncology diagnostics and academic workflows.
Spun out the DNA data storage technology application into an independent entity named Atlas Data Storage. This allows Twist to focus resources on its core commercial life sciences business while retaining minority equity upside, milestone payments, and royalties.
Expected impact: Accelerates the timeline to adjusted EBITDA breakeven for Twist by removing heavy R&D drag, while preserving long-term commercial upside in the cold-data archiving market.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Twist was selected as an integrated wet-lab CRO partner for the newly launched 'Amazon Bio Discovery' application. The platform routes AI-designed antibody candidates directly to Twist for physical synthesis and biophysical characterization, automatically returning experimental results to the AWS interface.
Renegotiated a prior 2022 agreement into a revised three-year collaboration. Twist acquired key licenses and assignments for long DNA writing technology and reagents to complement its synthesis portfolio. Ginkgo remains a major customer with preferential pricing and no minimum purchase volumes.
Terms: $15 million revised agreement with annual prepayments by Ginkgo.
Expanded collaboration to enable Element's AVITI sequencing systems and Trinity flowcells with Twist's library preparation and target enrichment workflows, including the launch of the Trinity Freestyle Fast Hybridization workflow.
Terms: Twist acts as the exclusive partner for these specific workflows; joint commercial and promotional activities.